Key clinical point: High-frequency episodic and low-frequency migraine share many characteristics.
Major finding: Approximately half of both subgroups had signs of depression.
Study details: An analysis of 16,789 patients in the Chronic Migraine Epidemiology and Outcomes Study.
Disclosures: Dr. Lipton disclosed financial relationships with Alder Biopharmaceuticals, Allergan (now AbbVie), Amgen, Biohaven, Dr. Reddy’s/Promius, Electrocore, Eli Lilly, eNeura Therapeutics, GlaxoSmithKline, Lundbeck (Alder), Merck, Pernix Therapeutics, Pfizer, Supernus, Teva, Trigemina, Axsome Therapeutics, Vector, and Vedanta. Dr. Charles disclosed he is a consultant to Amgen, Biohaven Pharmaceuticals, Eli Lilly, Lundbeck, and Novartis.
Lipton RB et al. AHS 2020, Abstract 813833.